Long Distance Call

Measuring the greatest distance between two tumours (Dmax) in a cancer patient's body imaged on CT scans is used as prognostic marker (a predictor of disease progression and how long a patient may survive) with conventional cancer therapies, but it hasn’t been closely looked at in the context of the increasingly promising CAR-T therapy (a kind of immunotherapy in which a cancer patient's own immune system is reprogrammed to attack their tumour). Here, taking this measurement in 39 patients before and after CAR-T therapy for the white blood cell cancer lymphoma, cancer in those with high Dmax progressed more quickly but it didn’t presage their overall survival

Read the published research article here

Written by Lindsey Goff

Lindsey Goff

Editor-in-Chief

Formerly immunologist for Cancer Research UK, Lindsey has since moved into the field of scientific publishing. She looks after all BPoD editorial matters.

• Image from work by Michael Winkelmann and colleagues
• Department of Radiology, University Hospital, LMU Munich, Munich, Germany
• Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)
• Published in Cancer Imaging, November 2025